FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $589,050 | +3.9% | 123,750 | +24.4% | 0.00% | 0.0% |
| Q1 2023 | $566,865 | -14.4% | 99,450 | +51.5% | 0.00% | 0.0% |
| Q4 2022 | $662,409 | +45.9% | 65,650 | +224.2% | 0.00% | 0.0% |
| Q3 2022 | $454,000 | -9.6% | 20,250 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $502,000 | -36.1% | 20,250 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $785,000 | -33.8% | 20,250 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,185,000 | +93.9% | 20,250 | +187.7% | 0.00% | +100.0% |
| Q2 2021 | $611,000 | -63.1% | 7,039 | -65.0% | 0.00% | -75.0% |
| Q1 2021 | $1,658,000 | -44.3% | 20,117 | -38.5% | 0.00% | -42.9% |
| Q4 2020 | $2,976,000 | +52.2% | 32,734 | -33.1% | 0.01% | +40.0% |
| Q3 2020 | $1,955,000 | +998.3% | 48,922 | +844.1% | 0.01% | – |
| Q2 2020 | $178,000 | +54.8% | 5,182 | 0.0% | 0.00% | – |
| Q1 2020 | $115,000 | -58.8% | 5,182 | -63.7% | 0.00% | -100.0% |
| Q4 2019 | $279,000 | – | 14,273 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |